The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million1.
Thankyou debull
I believe it was completed sometime ago,
https://www.physiomics.co.uk/wp-content/uploads/2019/04/2017-1-11-Company-Update-2.pdf
We are talking 2015-16 timelines here?
The candidate was CCT245737, which was renamed PNT737, then licensed out to Sierra by which time it was SRA737 https://www.edisongroup.com/research/sierra-oncology-returns-rights-to-sra737/31442/ Sierra bought out by GSK and then SRA737 rights were returned to SAR after GSK's purchase of Sierra. Or something along those lines!
What it does show is that PYC have been on this "Personal medicine" train for nearly a decade.
the original link was when i was looking at an article on immunology on the sar discussion group.
as an aside, i think trench123 said we still have an agreement with sar (or had that now completed?)
https://www.fiercebiotech.com/medtech/roche-picks-prenosis-newly-cleared-sepsis-ai-tool-distribution?itm_source=p****ly-api
This may not be relevant at all but thought it was interesting regarding what Ant said about the potential value of PYC/Doseme A.I tool
The ImmunoScore AI works with electronic health records to digest 22 pieces of clinical information and assigns a patient a risk level linked to the possibility of developing sepsis complications. (JazzIRT/GettyImage)
Following last week’s de novo clearance for the artificial intelligence program, Roche has stepped up to distribute Prenosis’ sepsis risk prediction tool through its diagnostic platforms.
The startup’s ImmunoScore software will be made available to hospital labs and emergency departments through Roche’s navify Algorithm Suite. The financial details of the agreement were not disclosed.
Yeah spread is 12% atm. Went down to 9% for a while. Not much liquidity then....1 sell of £232.20, took the bid down from 1.61p down to 1.2p. Bodes well if people start buying tho'
Can’t see any ramping tbh but valid point. Spread awful has been for a while was 30% a few days ago
1.40 close above and its game on
https://invst.ly/14digm
You got to love ramping traders, all part of the fun....
Just an 18% increase in the market cap to cover the spread then you look to make a profit...
LMOL
Nicely understated eh?!
JUST HURRY UP AND BUY
As was the case yesterday and this morning the maximum availability is just £2200
Good observation Hopoist ...i like it
Just need a little bit more trading volume.....
Yes I've been reading them....thank you.
PYC starting to hire additional staff to help manage new contracts is a positive and hopefully paves the way for further expansion....
No-one who was around at the time will forget when the original "personalised medicine RNS" came out and the SP exploded!
Hello hopist
And add to the fact its one of only a few stocks that INCREASED revenues in H1 + expected to hit £900,000 income for year ended June and pipeline of contracts now worth £1.5mln (the same as the current market value !)
Also read some of Ant123 posts,PYC seem to be at cutting edge of precision medicine
Bid is currently 1.101p on HL. And a triple bottom on the chart at 1.075. Hopefully a hammer candle by close of play today, which is a strong signal. Ticking up slowly....
Finally managed to buy more , HL was not giving a quote for large periods this morning , not sure if same applies to other people
I used my name because I founded the company.
Hi Ant,
Shame you didn't get a reply. Perhaps if your wife applied in her own name and used the company website careers section you might get some joy? It seems a shame to waste the opportunity.
Brilliant Post Ant - Thank You
Thank you Ant fr that great post.
So, PYC did not reply, not even to say thanks but not thanks? That is poor to be honest?
Is only £3200 today
Super post Ant
Alot to take in...thanks for taking the time
DeBull my wife was a Biotech analyst in The City. Keen to see the company prosper and not just for personal gain she asked me to communicate her willingness to help The Biostats development at PYC. She is also a data analyst and has previously written a paper An Algorithm to predict Protein Protein Binding when at Downing College Cambridge it has ben cited internationally. Cogent in Python and C I asked the Company if they would like some help. We didn't get a reply and I assumed that they had employed all the "muscle" they required. Which is a shame has her contacts extend into the sector where there are numerous opportunities to grow the business. I am not being critical at all but when companies like Avacta are undertaking PK and PD testing in Clinical Trials as indeed OXB we should be banging on their doors. PYC has shown that it understands the need to keep the market better informed and so I look forward to more announcements in the short to medium term. As I previously said DoseMeRX could be a game changer bur as with everything timing is always critical, others will follow suit and USP's and first to market edge are then lost. I have added a few more at these levels it makes sense to me as Personalised Medicine is definitely the way forward.
Focused on the delivery of biostatistics projects. Several complementary options are being pursued simultaneously to build out this new capability and a further update will be provided to the market towards the end of the current financial year